

## Supporting Information

# Synthesis and C–H Activation Reactions of Cyclometalated Copper(I) Complexes with NCN Pincer and 1,3,5-Triaza-7-Phosphaadamantane Derivatives: In Vitro Antimicrobial and Cytotoxic Activity

Leila Tabrizi \* †,‡, Hossein Chiniforoshan \*‡

† School of Chemistry, National University of Ireland, Galway, University Road, Galway, Ireland

‡ Department of Chemistry, Isfahan University of Technology, Isfahan, Iran

Corresponding author: Leila Tabrizi; Email: LEILA.TABRIZI@nuigalway.ie

Corresponding author: Hossein Chiniforoshan; Email: Chinif@cc.iut.ac.ir

## Contents

**Fig. S1.**  $^1\text{H}$  NMR spectrum of ligand (PTA-PhMe)(PF<sub>6</sub>) (DMSO-*d*<sub>6</sub>).

**Fig. S2.**  $^1\text{H}$  NMR spectrum of ligand (PTA-PhEt)(PF<sub>6</sub>) (DMSO-*d*<sub>6</sub>).

**Fig. S3.**  $^1\text{H}$  NMR spectrum of ligand (PTA-Ph*i*Pr)(PF<sub>6</sub>) (DMSO-*d*<sub>6</sub>).

**Fig. S4.**  $^1\text{H}$  NMR spectrum of complex **1** (DMSO-*d*<sub>6</sub>).

**Fig. S5.**  $^1\text{H}$  NMR spectrum of complex **2** (DMSO-*d*<sub>6</sub>).

**Fig. S6.**  $^1\text{H}$  NMR spectrum of complex **3** (DMSO-*d*<sub>6</sub>).

**Fig. S7.**  $^{13}\text{C}$  NMR spectrum of ligand (PTA-PhMe)(PF<sub>6</sub>) (DMSO-*d*<sub>6</sub>).

**Fig. S8.**  $^{13}\text{C}$  NMR spectrum of ligand (PTA-PhEt)(PF<sub>6</sub>) (DMSO-*d*<sub>6</sub>).

**Fig. S9.**  $^{13}\text{C}$  NMR spectrum of ligand (PTA-Ph*i*Pr)(PF<sub>6</sub>) (DMSO-*d*<sub>6</sub>).

**Fig. S10.**  $^{13}\text{C}$  NMR spectrum of complex **1** (DMSO-*d*<sub>6</sub>).

**Fig. S11.**  $^{13}\text{C}$  NMR spectrum of complex **2** (DMSO- $d_6$ ).

**Fig. S12.**  $^{13}\text{C}$  NMR spectrum of complex **3** (DMSO- $d_6$ ).

**Fig. S13.**  $^{31}\text{P} \{^1\text{H}\}$  NMR spectrum of ligand (PTA-PhMe)(PF<sub>6</sub>) (DMSO- $d_6$ ).

**Fig. S14.**  $^{31}\text{P} \{^1\text{H}\}$  NMR spectrum of ligand (PTA-PhEt)(PF<sub>6</sub>) (DMSO- $d_6$ ).

**Fig. S15.**  $^{31}\text{P} \{^1\text{H}\}$  NMR spectrum of ligand (PTA-Ph*i*Pr)(PF<sub>6</sub>) (DMSO- $d_6$ ).

**Fig. S16.**  $^{31}\text{P} \{^1\text{H}\}$  NMR spectrum of complex **1** (DMSO- $d_6$ ).

**Fig. S17.**  $^{31}\text{P} \{^1\text{H}\}$  NMR spectrum of complex **2** (DMSO- $d_6$ ).

**Fig. S18.**  $^{31}\text{P} \{^1\text{H}\}$  NMR spectrum of complex **3** (DMSO- $d_6$ ).

**Fig. S19.** TOF MS spectrum of ligand (PTA-PhMe)(PF<sub>6</sub>).

**Fig. S20.** TOF MS spectrum of ligand (PTA-PhEt)(PF<sub>6</sub>).


**Fig. S21.** TOF MS spectrum of ligand (PTA-Ph*i*Pr)(PF<sub>6</sub>).

**Fig. S22.** TOF MS spectrum of complex **1**.


**Fig. S23.** TOF MS spectrum of complex **2**.

**Fig. S24.** TOF MS spectrum of complex **3**.


**Fig. S25.** UV/Vis spectra of complexes **1-3** in MeOH/Tris-HCl buffer solution at room temperature




**Fig. S1.** <sup>1</sup>H NMR spectrum of ligand (PTA-PhMe)(PF<sub>6</sub>) (DMSO-*d*<sub>6</sub>).




**Fig. S2.**  $^1\text{H}$  NMR spectrum of ligand (PTA-PhEt)(PF<sub>6</sub>) (DMSO-*d*<sub>6</sub>).




**Fig. S3.** <sup>1</sup>H NMR spectrum of ligand (PTA-Ph<sup>i</sup>Pr)(PF<sub>6</sub>) (DMSO-*d*<sub>6</sub>).




**Fig. S4.** <sup>1</sup>H NMR spectrum of complex **1** (DMSO-*d*<sub>6</sub>).




**Fig. S5.**  $^1\text{H}$  NMR spectrum of complex **2** ( $\text{DMSO}-d_6$ ).




**Fig. S6.**  $^1\text{H}$  NMR spectrum of complex **3** ( $\text{DMSO}-d_6$ ).




**Fig. S7.**  $^{13}\text{C}$  NMR spectrum of ligand (PTA-PhMe)(PF<sub>6</sub>) (DMSO-*d*<sub>6</sub>).




**Fig. S8.** <sup>13</sup>C NMR spectrum of ligand (PTA-PhEt)(PF<sub>6</sub>) (DMSO-*d*<sub>6</sub>).




**Fig. S9.**  $^{13}\text{C}$  NMR spectrum of ligand (PTA-Ph<sup>i</sup>Pr)(PF<sub>6</sub>) (DMSO-*d*<sub>6</sub>).




**Fig. S10.** <sup>13</sup>C NMR spectrum of complex 1 (DMSO-*d*<sub>6</sub>).




**Fig. S11.**  $^{13}\text{C}$  NMR spectrum of complex 2 ( $\text{DMSO}-d_6$ ).




**Fig. S12.** <sup>13</sup>C NMR spectrum of complex 3 (*DMSO-d*<sub>6</sub>).




**Fig. S13.**  ${}^3\text{P}$  { ${}^1\text{H}$ } NMR spectrum of ligand (PTA-PhMe)(PF<sub>6</sub>) (DMSO-*d*<sub>6</sub>).




**Fig. S14.**  ${}^{31}\text{P}$  { ${}^1\text{H}$ } NMR spectrum of ligand (PTA-PhEt)(PF<sub>6</sub>) (DMSO-*d*<sub>6</sub>).




**Fig. S15.**  ${}^3\text{P}$  { ${}^1\text{H}$ } NMR spectrum of ligand (PTA-Ph<sup>i</sup>Pr)(PF<sub>6</sub>) (DMSO-*d*<sub>6</sub>).




**Fig. S16.**  ${}^{31}\text{P}$   $\{{}^1\text{H}\}$  NMR spectrum of complex **1** ( $\text{DMSO}-d_6$ ).




**Fig. S17.**  ${}^3\text{P}\ \{{}^1\text{H}\}$  NMR spectrum of complex **2** ( $\text{DMSO}-d_6$ ).




**Fig. S18.**  ${}^3\text{1}\text{P}$   $\{{}^1\text{H}\}$  NMR spectrum of complex 3 ( $\text{DMSO}-d_6$ ).




**Fig. S19.** TOF MS spectrum of ligand (PTA-PhMe)(PF<sub>6</sub>).




**Fig. S20.** TOF MS spectrum of ligand (PTA-PhEt)(PF<sub>6</sub>).




**Fig. S21.** TOF MS spectrum of ligand (PTA-Ph<sup>i</sup>Pr)(PF<sub>6</sub>).




**Fig. S22.** TOF MS spectrum of complex 1.



**Fig. S23.** TOF MS spectrum of complex **2**.



**Fig. S24.** TOF MS spectrum of complex 3.



**Fig. S25.** UV/Vis spectra of complexes **1-3** in MeOH/Tris–HCl buffer solution at room temperature